An observational study in Hereditary Multiple Melanoma and Melanoma (Skin), sponsored by Leeds Cancer Centre at St. James's University Hospital. Status unknown at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2013-08-12.
Sponsored by Leeds Cancer Centre at St. James's University Hospital · Observational
RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future.
PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma.
OBJECTIVES:
OUTLINE: This is a case-control, multicenter study.
Participants complete 2 questionnaires and assist in the creation and expansion of a family pedigree. Blood samples are examined for melanoma susceptibility gene mutations, including CDK4 and CDKN2A.
Participants are also examined for moles and photographed. Physical variables (e.g., skin, eye, and hair pigmentation) and sun damage (solar lentigines and freckling) are also noted.
If available, tissue samples are examined for Clark level, Breslow thickness, and frequency of mitoses. Peri-lesional skin from tumors is examined by p53 staining.
Participants are followed periodically to monitor cancer development.
Peer reviewed and funded or endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 5,000 participants will be accrued for this study.
135 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 18 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 300 across 27 observational studies indexed under Melanoma, Cutaneous Malignant.
Browse Melanoma, Cutaneous Malignant studies →Leeds Cancer Centre at St. James's University Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
DISEASE CHARACTERISTICS:
Meets one of the following criteria:
Prior multiple primary melanomas
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Predictive significance of melanoma susceptibility gene (MSG) mutations in the CDKN2A gene
Susceptibility to other types of cancer as a feature of MSG mutations
Risk of other types of cancers in mutation carriers
Environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers
The record gives a start of Jan 1989 and a primary completion of Dec 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Melanoma, Cutaneous Malignant →
Leeds Cancer Centre at St. James's University Hospital